Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | TDO2 | P48775 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254677 | 0.81 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL3256063 | 0.81 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL17842404 | 0.81 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL3675762 | 0.81 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL12568801 | 0.81 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL18449599 | 0.80 | IDO1 (0.42) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL6824093 | 0.80 | CES2 (0.44) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL30682740 | 0.80 | IDO1 (0.42) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL1999868 | 0.78 | IDO1 (0.43) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL29768740 | 0.78 | IDO1 (0.43) | IDO1TDO2CES2CES1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | claimed |
| CN-114369070-B | Preparation process of rufinamide | 海南医学院 | 2023-04-14 | — | — | CN | claimed |
| CN-114369070-A | Preparation process of rufinamide | 海南医学院 | 2022-04-19 | — | — | CN | claimed |
| CN-215440287-U | Post-treatment device for difluorobenzylamine and trifluorobenzylamine | 弈柯莱(台州)药业有限公司 | 2022-01-07 | — | — | CN | claimed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | claimed |
| EP-3735276-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-11-11 | — | — | EP | claimed |
| CN-111615404-A | Compounds and methods for transmembrane delivery of molecules | 艾博森斯有限公司 | 2020-09-01 | — | — | CN | claimed |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | disclosed |
| CN-117327091-A | Synthesis method of Rayleigh Lu Geli | 浙江天宇药业股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-116826293-A | Battery top cover and battery pack and vehicle with battery top cover | 中国第一汽车股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116419937-A | Composition for forming resist underlayer film | 日产化学株式会社 | 2023-07-11 | — | — | CN | disclosed |
| CN-114369070-B | Preparation process of rufinamide | 海南医学院 | 2023-04-14 | — | — | CN | disclosed |
| CN-114369070-B | Preparation process of rufinamide | 海南医学院 | 2023-04-14 | — | — | CN | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003051897-A1 | NUCLEOSIDE ANALOG LIBRARIES AND COMPOUNDS | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-0427445-A1 | Benzylideneaminoxyalkanoic acid (thio) amide derivative, process for preparing the same and herbicide | UBE INDUSTRIES, LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | LDLR, NPC1L1, ABCB4 | IDO1 4861/4885TDO2 4652/4885CES2 516/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | IDO1 4861/4885TDO2 4652/4885CES2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.